Agreement gives Crescent an exclusive option to develop and market products from intellectual property that was invented at the University of Limerick and the University of Wyoming
Crescent Diagnostics has signed an intellectual property option agreement with DeltaNu.
This agreement gives Crescent an exclusive option to develop and market products from intellectual property that was invented at the University of Limerick and the University of Wyoming and is jointly held by Crescent and DeltaNu.
The intellectual property describes a novel way to use Raman spectroscopy to diagnose bone health conditions like osteoporosis.
"We are very happy to conclude an agreement like this - it formalizes a great working relationship we've had with DeltaNu for the past two years," says Ernest Poku, CEO of Crescent Diagnostics.
"The applications for Raman spectroscopy are growing," says Keith Carron, CEO of DeltaNu, "and DeltaNu is fortunate to partner with a leader like Crescent as it brings this important technology to the market".
The companies continue to work together on developing bone health tests and the associated Raman instrumentation and analytical techniques.
